Business Context and Reporting Period
This Form 8-K Current Report from Silexion Therapeutics Corp covers events occurring on July 20, 2026, with the report filed on July 21, 2026. The filing details the outcomes of an extraordinary general meeting of shareholders reconvened on July 20, 2026, following an adjournment on July 13, 2026, due to a lack of quorum.
Key Financial Metrics
This filing is a corporate governance report and does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses on capital structure adjustments and shareholder voting results.
Material Changes and Shareholder Actions
Shareholders approved two significant proposals at the reconvened meeting, where 230,276 ordinary shares (approximately 21.7% of issued shares) were present:
- Proposal 1 (New Warrant Exercisability): Approved with 93.3% of votes in favor. This authorizes the exercise of 399,020 new Series C and D ordinary warrants at $5.00 per share and 13,966 placement agent warrants at $6.25 per share. These figures reflect adjustments for a 1-for-10 reverse share split completed on May 28, 2026.
- Proposal 2 (Authorized Share Capital Increase): Approved with 89.8% of votes in favor. The authorized share capital was increased by 10,000,000 ordinary shares, raising the total from 5,900,000 to 15,900,000 shares. The total authorized capital value increased from $796,500 to $2,146,500.
Guidance, Outlook, and Risks
The filing does not provide management commentary on future financial guidance, operational outlook, or specific risk factors. The primary contingency addressed was the initial failure to achieve a quorum on July 13, 2026, which was resolved by reconvening the meeting under Article 21.3 of the Articles of Association, allowing the shareholders present to constitute a quorum after a 30-minute lapse.
Key Facts for Investor Verification
- Verify the impact of the approved warrant exercises on potential future dilution and cash inflow.
- Confirm the updated authorized share count of 15,900,000 ordinary shares.
- Note that the warrant exercise prices ($5.00 and $6.25) and share counts are adjusted for the May 28, 2026, 1-for-10 reverse split.
- Review the attached Exhibit 3.1 (Memorandum Amendment) for the full legal terms of the capital increase.